164 related articles for article (PubMed ID: 19921476)
21. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.
Bilgin Doğru E; Dizdar Y; Akşit E; Ural F; Şanlı Ö; Yasasever V
Tumour Biol; 2014 Nov; 35(11):11647-53. PubMed ID: 25139103
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of MMP-13 and EMMPRIN in epithelial odontogenic lesions.
de Andrade Santos PP; Nonaka CFW; Barboza CAG; Pereira Pinto L; de Souza LB
Eur Arch Otorhinolaryngol; 2019 Nov; 276(11):3203-3211. PubMed ID: 31440816
[TBL] [Abstract][Full Text] [Related]
23. Stage-specific prognostic biomarkers in melanoma.
Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
[TBL] [Abstract][Full Text] [Related]
24. EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas.
Tsai WC; Chen Y; Huang LC; Lee HS; Ma HI; Huang SM; Sytwu HK; Hueng DY
J Neurooncol; 2013 Sep; 114(3):281-90. PubMed ID: 23817808
[TBL] [Abstract][Full Text] [Related]
25. Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma.
Sheen YS; Liao YH; Lin MH; Chiu HC; Jee SH; Liau JY; Chang YL; Chu CY
PLoS One; 2016; 11(1):e0147431. PubMed ID: 26796627
[TBL] [Abstract][Full Text] [Related]
26. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma.
Xu X; Chen L; Guerry D; Dawson PR; Hwang WT; VanBelle P; Elder DE; Zhang PJ; Ming ME; Schuchter L; Gimotty PA
Clin Cancer Res; 2012 Jan; 18(1):229-37. PubMed ID: 22096024
[TBL] [Abstract][Full Text] [Related]
27. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.
Xin X; Zeng X; Gu H; Li M; Tan H; Jin Z; Hua T; Shi R; Wang H
Sci Rep; 2016 Sep; 6():32804. PubMed ID: 27608940
[TBL] [Abstract][Full Text] [Related]
28. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle.
Mishra B; Kizaki K; Koshi K; Ushizawa K; Takahashi T; Hosoe M; Sato T; Ito A; Hashizume K
Reprod Biol Endocrinol; 2010 Jun; 8():60. PubMed ID: 20540754
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
30. The expression of MMP-2 and Ki-67 in head and neck melanoma, and their correlation with clinic-pathologic indices.
Kamyab-Hesari K; Mohtasham N; Aghazadeh N; Biglarian M; Memar B; Kadeh H
J Cancer Res Ther; 2014; 10(3):696-700. PubMed ID: 25313763
[TBL] [Abstract][Full Text] [Related]
31. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
32. Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients' prognosis.
Yang X; Dai J; Li T; Zhang P; Ma Q; Li Y; Zhou J; Lei D
Oral Oncol; 2010 Oct; 46(10):755-60. PubMed ID: 20850374
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients.
Du ZM; Hu CF; Shao Q; Huang MY; Kou CW; Zhu XF; Zeng YX; Shao JY
Int J Cancer; 2009 Oct; 125(8):1832-41. PubMed ID: 19582878
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas.
Gu J; Zhang C; Chen R; Pan J; Wang Y; Ming M; Gui W; Wang D
Eur J Pediatr; 2009 Jun; 168(6):705-10. PubMed ID: 18795327
[TBL] [Abstract][Full Text] [Related]
35. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer.
Boye K; Nesland JM; Sandstad B; Haugland Haugen M; Mælandsmo GM; Flatmark K
Br J Cancer; 2012 Aug; 107(4):667-74. PubMed ID: 22782346
[TBL] [Abstract][Full Text] [Related]
36. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.
van den Oord JJ; Paemen L; Opdenakker G; de Wolf-Peeters C
Am J Pathol; 1997 Sep; 151(3):665-70. PubMed ID: 9284814
[TBL] [Abstract][Full Text] [Related]
37. EMMPRIN expression in tongue squamous cell carcinoma.
Huang Z; Huang H; Li H; Chen W; Pan C
J Oral Pathol Med; 2009 Jul; 38(6):518-23. PubMed ID: 19473445
[TBL] [Abstract][Full Text] [Related]
38. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
39. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
Oba J; Nakahara T; Hayashida S; Kido M; Xie L; Takahara M; Uchi H; Miyazaki S; Abe T; Hagihara A; Moroi Y; Furue M
J Am Acad Dermatol; 2011 Dec; 65(6):1152-60. PubMed ID: 21700362
[TBL] [Abstract][Full Text] [Related]
40. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
